Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Skip Nav Destination
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
December 30, 2021
Content License:Private